Bayer AG NA (BAYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bayer AG NA (BAYN) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.69 Billion) by net assets (€29.70 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bayer AG NA - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Bayer AG NA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bayer AG NA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bayer AG NA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carvana Co
NYSE:CVNA
|
0.102x |
|
ASSA ABLOY AB ser. B
LSE:0R87
|
0.074x |
|
CSL Limited
F:CSJ
|
0.039x |
|
Occidental Petroleum Corporation
NYSE:OXY
|
0.076x |
|
Becton Dickinson and Company
NYSE:BDX
|
0.026x |
|
CBRE Group Inc Class A
NYSE:CBRE
|
0.089x |
|
Ciena Corp
NYSE:CIEN
|
0.082x |
|
Compagnie de Saint-Gobain S.A.
PA:SGO
|
0.060x |
Annual Cash Flow Conversion Efficiency for Bayer AG NA (1998–2024)
The table below shows the annual cash flow conversion efficiency of Bayer AG NA from 1998 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €32.05 Billion | €7.37 Billion | 0.230x | +48.63% |
| 2023-12-31 | €33.08 Billion | €5.12 Billion | 0.155x | -15.10% |
| 2022-12-31 | €38.93 Billion | €7.09 Billion | 0.182x | +18.76% |
| 2021-12-31 | €33.17 Billion | €5.09 Billion | 0.153x | -3.93% |
| 2020-12-31 | €30.70 Billion | €4.90 Billion | 0.160x | -7.53% |
| 2019-12-31 | €47.52 Billion | €8.21 Billion | 0.173x | +0.68% |
| 2018-12-31 | €46.15 Billion | €7.92 Billion | 0.172x | -22.26% |
| 2017-12-31 | €36.86 Billion | €8.13 Billion | 0.221x | -22.56% |
| 2016-12-31 | €31.90 Billion | €9.09 Billion | 0.285x | +5.23% |
| 2015-12-31 | €25.45 Billion | €6.89 Billion | 0.271x | -5.77% |
| 2014-12-31 | €20.22 Billion | €5.81 Billion | 0.287x | +15.61% |
| 2013-12-31 | €20.80 Billion | €5.17 Billion | 0.249x | +1.84% |
| 2012-12-31 | €18.57 Billion | €4.53 Billion | 0.244x | -7.05% |
| 2011-12-31 | €19.27 Billion | €5.06 Billion | 0.263x | -14.06% |
| 2010-12-31 | €18.90 Billion | €5.77 Billion | 0.306x | +7.72% |
| 2009-12-31 | €18.95 Billion | €5.38 Billion | 0.284x | +28.45% |
| 2008-12-31 | €16.34 Billion | €3.61 Billion | 0.221x | -13.28% |
| 2007-12-31 | €16.82 Billion | €4.28 Billion | 0.255x | -22.14% |
| 2006-12-31 | €12.85 Billion | €4.20 Billion | 0.327x | +1.90% |
| 2005-12-31 | €10.90 Billion | €3.50 Billion | 0.321x | +62.15% |
| 2004-12-31 | €12.37 Billion | €2.45 Billion | 0.198x | -25.85% |
| 2003-12-31 | €12.31 Billion | €3.29 Billion | 0.267x | -6.66% |
| 2002-12-31 | €15.47 Billion | €4.42 Billion | 0.286x | +26.11% |
| 2001-12-31 | €17.05 Billion | €3.87 Billion | 0.227x | +20.15% |
| 2000-12-31 | €16.42 Billion | €3.10 Billion | 0.189x | -11.92% |
| 1999-12-31 | €15.18 Billion | €3.25 Billion | 0.214x | -3.86% |
| 1998-12-31 | €12.78 Billion | €2.85 Billion | 0.223x | -- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more